CTHRC1 and cancer: Results of the analysis revealed that CTHRC1 also significantly (p > 0.05) overexpressed in HNSC, KIRC, LIHC, LUAD, STAD, and UCEC patients of different clinicopathological characteristics stratified by cancer staging (stage 1, 2, 3, and 4), race grouping (Caucasian, African-American, and Asian), gender grouping (male and female), and age grouping (20–40 years, 41–60 years, 61–80 years, and 81–100 years) (Figs. 4, 5, 6, 7, 8, 9).